JPMorgan analyst Jessica Fye lowered the firm’s price target on Crinetics (CRNX) to $52 from $53 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect slightly higher spending assumptions.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics management to meet with Cantor Fitzgerald
- Crinetics receives Orphan Drug designation for atumelnant in CAH
- Crinetics’ treatment of CAH granted FDA orphan designation
- Crinetics Pharma’s Earnings Call: Progress Amid Challenges
- Crinetics Pharmaceuticals: A Promising Buy with Strategic Initiatives and Upcoming Milestones